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Abstract
Background:  Actinobacillus pleuropneumoniae, the causative bacterial agent of porcine
pleuropneumonia, produces Apx toxins which belong to RTX toxin family and are recognized as
the major virulence factors. So far, their target receptor(s) has not been identified and the disease
cytopathogenesis remains poorly understood. Production of an active Apx toxin and
characterization of its toxic activity constitute the premises necessary to the description of its
interaction with a potential receptor. From this point of view, we produced an active recombinant
ApxIIIA toxin in order to characterize its toxicity on peripheral blood mononucleated cells
(PBMCs) isolated from several species.
Findings: Toxin preparation exercises a strong cytotoxic action on porcine PBMCs which is
directly related to recombinant ApxIIIA since preincubation with polymyxin B does not modify the
cytotoxicity rate while preincubation with a monospecific polyclonal antiserum directed against
ApxIIIA does. The cell death process triggered by ApxIIIA is extremely fast, the maximum rate of
toxicity being already reached after 20 minutes of incubation. Moreover, ApxIIIA cytotoxicity is
species-specific because llama, human, dog, rat and mouse PBMCs are resistant. Interestingly,
bovine and caprine PBMCs are slightly sensitive to ApxIIIA toxin too. Finally, ApxIIIA cytotoxicity
is cell type-specific as porcine epithelial cells are resistant.
Conclusion: We have produced an active recombinant ApxIIIA toxin and characterized its specific
cytotoxicity on porcine PBMCs which will allow us to get new insights on porcine pleuropneumonia
pathogenesis in the future.
Background
Actinobacillus pleuropneumoniae is the bacterial causative
agent of porcine pleuropneumonia, a frequent and highly
infectious disease generating significant economic losses
related to deficits in zootechnical profits and intensive use
of antibiotics [1,2]. Bacterium virulence factors include
exotoxins Apx («A. pleuropneumoniae RTX») -IA, -IIA, -IIIA
and -IVA, lipopolysaccharides, polysaccharidic capsule,
fimbriae, iron collecting systems, proteases, superoxide dis-
mutase, etc [3]. Among these weapons, Apx toxins are rec-
ognized as major virulence factors. These exotoxins belong
to RTX (Repeats in ToXin) proteins family. These latter mol-
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ecules share the same structural characteristic which is a
series of glycine- and aspartate-rich nonapeptide repeats
which constitute the main calcium-binding sites of the pro-
tein [4]. If the apxIVA gene is not disrupted by an insertion
element [5], all serotypes are able to synthesize ApxIVA
(only in vivo) whose autocatalytic and cross-linking activi-
ties [6] make it different from other Apx toxins which are of
the pore-forming toxin (PFT) type.
Some of the Apx toxic activities were already detected by
precedent studies. It is accepted that: (i) ApxIA exerts a
strong hemolytic activity and a strong cytotoxic activity,
(ii) ApxIIA possesses a weak hemolytic activity and a mod-
erate cytotoxic activity, and (iii) ApxIIIA does not display
a haemolytic activity but a strong cytotoxic activity on por-
cine neutrophils and pulmonary alveolar macrophages
(PAM) [3,7-10]. Contrary to LtxA (Aggegatibacter actino-
mycetemcomitans), LktA (Mannheimia haemolytica), HlyA
(Escherichia coli) and CyaA (Bordetella pertussis) RTX toxins
for which it was shown that they acted through β2-integrin
receptors to induce a cytotoxic effect on leukocytes [11-
18], the target receptor of PFT Apx toxins has not been
identified yet and cytopathogenesis of associated disease
remains poorly understood. In this perspective, active Apx
toxin production and characterization of its toxic action
constitute premises necessary to the description of its
interaction with a potential receptor.
Methods
Preparation of rApxIIIA toxin
Plasmid pJFF1003, containing ApxIIIA gene, was kindly
provided from P. Kuhnert and J. Frey (Institute of Veteri-
nary Bacteriology, University of Bern, Switzerland). This
plasmid contains, inserted in the vector pET14b, the apxI-
IICABD operon controlled by a strong constitutive endog-
enous promoter [19]. Transformed E. coli Rosetta™
(Novagen, Belgium) were seeded on Luria-Bertani (LB)
agar plates with ampicillin (50 μg/ml) and incubated
overnight at 37°C. Several clones were then cultivated,
each one in 200 ml LB broth with ampicillin (50 μg/ml)
and the Complete® protease inhibitor cocktail (Roche,
Belgium), one tablet for 50 ml culture with shaking (200
rpm) at 37°C until an optic density of 1.2 at 600 nm was
reached. Next, the toxin was concentrated following Maier
and collaborators protocol [19] and finally dissolved in
sterile DPBS (1 ml for 200 ml of starting culture) (Lonza
Biowhittaker, Belgium). The ImageJ 1.37c software [20]
gave an estimation of ~100 μg/ml (~0.83 μM, ~5.1014 tox-
ins/ml) ApxIIIA (120 kDa) after electrophoresis on
Coomassie blue-stained sodium dodecyl sulfate gels (Inv-
itrogen, Belgium) by using 1 μg of BSA as standard.
PBMCs recovery from several species
Fresh blood rescued from five pigs (Sus scrofa domesticus,
Piétrain), three wild boars (Sus scrofa scrofa), two cows
(Bos Taurus), two goats (Capra hircus), one llama (Lama
pacos), a man, two dogs (Canis familiaris), ten mice (Mus
musculus) and two rats (Rattus norvegicus) were taken in
BD Vacutainer® citrate tube (BD, Belgium). Peripheral
blood mononucleated cells (PBMCs) were then extracted
by the Accuspin™ System-Histopaque® 1077 (Sigma, Bel-
gium) according to the manufacturer's protocol and resus-
pended to a density of 2.106 cells/ml in RPMI-1640 with
25 mM Hepes and L-glutamine (Lonza Biowhittaker, Bel-
gium), supplemented with 10% [v/v] heat-inactivated
fetal bovine serum (Lonza BioWhittaker, Belgium) along
with amphotericin-B 250 μg/ml (Gibco, Belgium) and
penicillin-streptomycin 10.000 U/ml (Lonza BioWhit-
taker, Belgium).
Cell culture
PK15 cell line was purchased from the ATCC collection
(CCL-33), maintained in EMEM (Lonza BioWhittaker,
Belgium) supplemented with 10% [v/v] heat-inactivated
fetal bovine serum (Lonza BioWhittaker, Belgium) along
with amphotericin-B 250 μg/ml (Gibco, Belgium) and
penicillin-streptomycin 10.000 U/ml (Lonza BioWhit-
taker, Belgium), at 37°C in a humidified 5% CO2 incuba-
tor and isolated from the flask after treatment with the
Cell Dissociation Solution Non Enzymatic (Sigma, Bel-
gium).
Surface labeling of porcine leukocytes and flow cytometry 
analysis
Localization of the porcine PBMCs on the SSC (Side Scat-
ter)/FSC (Forward Scatter) dot plot was accomplished by
a PoLFA-1 cell-surface labeling. First, 105  cells were
washed three times with 1 ml DPBS, 1% BSA, by a centrif-
ugation of 5 minutes at 200 g. Next, cellular surface was
blocked during 20 minutes on ice with 1 ml DPBS, 1%
BSA, and then primary antibody (mouse anti-porcine
CD18, MCA1972, Abd Serotec, Belgium) was added at 1/
1,000 dilution and incubated for 20 minutes on ice. Cells
were washed again three times with DPBS, 1% BSA, and
the secondary antibody (AlexaFluor® 488 goat anti-mouse
IgG, Molecular Probes, USA) was added at 1/1,000 dilu-
tion for 20 minutes on ice. Finally, leukocytes were
washed three times with DPBS, resuspended into 500 μl
of this buffer and analyzed for AlexaFluor® 488 fluores-
cence on a BD FACSCanto™ flow cytometry system using
BD FACSDiva software (Becton Dickinson, Belgium).
Labeling with an isotype-matched non pertinent murine
mAb was used as negative control.
Cytotoxicity analysis by flow cytometry
In order to undertake the cytotoxic assays, 5 μg rApxIIIA
(50 μl stock solution) were added to 105 PBMCs in 50 μl
of RPMI-1640 or 105 PK15 cells in 50 μl of EMEM. The
positive and negative controls of cell death were obtained
by adding respectively 50 μl paraformaldehyde 10%
(Sigma, Belgium) and 50 μl RPMI-1640 or EMEM (mock-
exposed) to 105 cells into 50 μl medium. Development ofBMC Research Notes 2008, 1:121 http://www.biomedcentral.com/1756-0500/1/121
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cell death was stopped by the addition of 1 ml of ice-cold
DPBS and pellets were then suspended into 495 μl DPBS
plus 5 μl propidium iodide (PI) (250 μg/ml) (Invitrogen,
Belgium), after a centrifugation of 5 minutes at 200 g.
Finally, the cells susceptibility to rApxIIIA was assayed by
measuring PI fluorescence on the BD FACSCanto™ flow
cytometry system. Each experiment was made in triplicate.
Findings
Flow cytometric probing of toxin-induced alterations of 
porcine PBMCs
Flow cytometric analysis of physical characteristics of por-
cine PBMCs, using SSC/FSC dot plot, revealed a principal
cell population (P1) (Fig. 1A). Anti-porcine (Po) CD18
mAb bound near 100% of P1 cells (Fig. 1B), confirming
that it corresponds to the porcine PBMCs population. P1
is characterized by FSC and SSC values which presumably
correspond to porcine lymphocytes.
After a one hour-incubation with 5 μg rApxIIIA crude
toxin, the SSC/FSC signature of P1 PBMCs is displaced
towards a P2 population with reduced FSC values (Fig.
1A). Again, surface labeling with the anti-PoCD18 mAb
showed that near 100% of P2 cells correspond to PBMCs
(Fig. 1B). Exposition to rApxIIIA thus resulted in a reduc-
tion in size with no modification of granularity (SSC).
This cellular morphologic change is compatible with the
induction of a cell-death process by ApxIIIA [21].
Moreover, in the PI/FSC dot plot (Fig. 1C), it was observed
that P2 is subdivided into a very strongly stained popula-
tion (P2B) and another showing an intermediate labeling
(P2A), presumably corresponding to intermediate stages
of cell damage. The cell counts/PI histogram (Fig. 1D)
revealed that approximately 70% of porcine PBMCs
underwent a cell-death process.
Kinetics of crude toxin preparation cytotoxicity on porcine 
PBMCs
Kinetics of the cytotoxic action was characterized by incu-
bating 105 porcine PBMCs in 50 μl of RPMI-1640 with
0.3125 μg rApxIIIA crude toxin and stopping the exposure
after 1, 10, 20, 30, 45, 60, 90 and 120 minutes. The results
show that cell poisoning is an extremely rapid process.
Indeed, one minute incubation is already sufficient to
lead to a cytotoxicity rate of approximatively ten percents
(Fig. 2). Moreover, a plateau of maximal cell death
(~35%) is reached after 20 minutes of incubation (Fig. 2).
This speed of action was also observed in a precedent
study in which marked morphological changes occurred
in pulmonary alveolar macrophages within ten minutes
of exposure to ApxIIIA [22]. After this period, the toxicity
rate seems to increase slightly, following the kinetics of
negative controls (Fig. 2).
Dose dependent-cytotoxic activity of crude toxin 
preparation on porcine PBMCs
As expected, porcine PBMCs were damaged in a concen-
tration-dependent manner when exposed to different
dilutions of rApxIIIA crude toxin. Maximum of toxicity
rate (~80%) was obtained with the addition of 5 μg toxin
(50 μl stock solution) to 50 μl RPMI-1640 with 106 por-
cine PBMCs (Fig. 3). Moreover, the curve of the graph
shows that the cytopathogenic rate obtained for this dilu-
tion seems to reach a plateau of maximum toxicity (Fig.
3).
Effect of toxin preincubation with polymyxin B on 
cytotoxicity
In order to examine whether the LPS content possibly
present in the crude toxin preparation contributed to the
cytotoxicity detected, the toxin preparation was preincu-
bated during one hour at 37°C with polymyxin B (50 and
100 μg/ml) (Sigma, Belgium) before assaying its cytotoxic
activity towards porcine PBMCs. This assay clearly shows
that preincubation with polymyxin B does not decrease
the cytotoxicity rate and thus, that lipopolysaccharides
potentially present in the toxin preparation are not
responsible of cell injury induction (Fig. 4A). As negative
control, porcine PBMCs were incubated, during the same
duration, with the same polymyxin B concentrations
without adding the toxin solution.
Cytotoxicity is due to rApxIIIA
Ultimate assignment of the cytotoxic activity to rApxIIIA
was made by neutralizing the crude toxin preparation
effect via a preincubation of 30 minutes at 4°C with a rab-
bit monospecific polyclonal antibody directed against
ApxIIIA (1/1,000) friendly provided by Professor J. Frey
(Institute of Veterinary Bacteriology, University of Bern,
Switzerland) [23]. Incubation of the PBMCs during one
hour at 37°C with the preincubated mix (crude toxin
preparation/antiserum) resulted in a dramatic abatement
in the cytopathogenic activity of two different rApxIIIA
amounts (0.16 and 0.31 μg), these latter respectively caus-
ing ~30 and ~50% of the maximum cell damage recorded
(Fig. 3) when the antiserum was omitted (Fig. 4B). Incu-
bating porcine PBMCs in the same conditions with the
monospecific polyclonal antiserum directed against ApxI-
IIA did not alter the baseline cell death rate (Fig. 4B).
These results suggest that the cytotoxic activity associated
with our crude toxin preparation is due to rApxIIIA.
rApxIIIA-induced cytotoxicity is species-specific
When 105 PBMCs purified from pigs, wild boars, cows,
goats, llamas, man, dogs, mice and rats were exposed for
one hour to 5 μg rApxIIIA crude toxin, striking differences
in susceptibility were enlightened (Fig. 5). Human, llama,
dog, mouse and rat PBMCs were totally resistant, whereasBMC Research Notes 2008, 1:121 http://www.biomedcentral.com/1756-0500/1/121
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A. Spreading of porcine PBMCs elements in SSC/FSC dot plot after rApxIIIA addition Figure 1
A. Spreading of porcine PBMCs elements in SSC/FSC dot plot after rApxIIIA addition. P1 (red) and P2 (blue) pop-
ulations represent mock- (RPMI-1640) and rApxIIIA-exposed porcine PBMCs respectively. X-axis and Y-axis represent FSC 
and SSC values respectively. B. Surface expression of LFA-1 by mock- (P1, red) and rApxIIIA (P2, blue) exposed porcine 
PBMCs. Surface labeling was made with anti-PoCD18 mAb MCA1972. Labeling with an isotype-matched nonpertinent murine 
mAb was used as negative control (black). X-axis shows fluorescence intensity (Alexa 488) and the Y-axis represents cell 
count. The percentage of Alexa 488-positive cells is indicated within the panels. C. Spreading of porcine PBMCs elements in PI/
FSC dot plot after rApxIIIA addition. P1 (red) and P2 (blue) populations represent mock- and rApxIIIA-exposed porcine PBMCs 
respectively. Two subpopulations can be observed for P2: the first shows an intermediate labeling (P2A) while the second (P2B) 
is very strongly tagged, corresponding to intermediate and final stages of cell death respectively. The bar represents the posi-
tivity threshold. X-axis and Y-axis represent FSC and PI-fluorescence values. D. Distribution of PI labeling among mock- (red) 
and rApxIIIA-exposed (blue) porcine PBMCs. The P2A and P2B subpopulations are readily detected. X-axis shows fluorescence 
intensity (PI) and the Y-axis represents cell count. Percentage of PI-positive cells is indicated within the panels.
A.                                                                  B.   
                  
C.                                                                  D.   
          
P1 
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bovine and caprine PBMCs showed slight susceptibility
(~10% PI-positive cells) compared to pig (~60%) and
wild boar (~50%) cells.
rApxIIIA-induced cytotoxicity is leukocytes-specific
Finally, exposing PK15 porcine epithelial cells to 5 μg
rApxIIIA did not result in the induction of cell death,
which suggests that cytotoxic activity is restricted to por-
cine leukocytes (data not shown).
Conclusion
We have produced a recombinant ApxIIIA toxin in order
to evaluate its possible cytotoxic activity towards porcine
PBMCs. After one-hour duration incubation at 37°C,
PBMCs show a reduction in size and accumulate propid-
ium iodide, both characteristics being compatible with
Kinetics of porcine PBMCs death upon exposition to rApxI- IIA crude toxin preparation Figure 2
Kinetics of porcine PBMCs death upon exposition to 
rApxIIIA crude toxin preparation. Kinetics of the cyto-
toxic action was characterized by incubating porcine PBMCs 
with 0.31 μg rApxIIIA crude toxin preparation and stopping 
the exposure after 1, 10, 20, 30, 45, 60, 90 and 120 minutes. 
Horizontal axis, duration of exposition; vertical axis, fraction 
of PI-positive PBMCs. Basal cell death rate was measured 
from mock-exposed (RPMI-1640) PBMCs for comparison. 
Values are means ± SDs from three representative experi-
ments.
Dose-dependent cytotoxicity of rApxIIIA on porcine PBMCs Figure 3
Dose-dependent cytotoxicity of rApxIIIA on porcine 
PBMCs. The fraction of PI-positive cells was measured one 
hour after exposition to serial dilutions of the crude toxin 
preparation. Values are means ± SDs from three representa-
tive experiments. C-, mock-exposed (RPMI-1640) porcine 
PBMCs incubated for one hour (negative control); C+, para-
formaldehyde-exposed PBMCs (positive control).
A. Effect of polymyxin B incorporation on rApxIIIA-contain- ing crude toxin preparation cytotoxicity towards porcine  PBMCs Figure 4
A. Effect of polymyxin B incorporation on rApxIIIA-
containing crude toxin preparation cytotoxicity 
towards porcine PBMCs. The fraction of PI-positive cells 
was measured by flow cytometry after a two-hour exposi-
tion (i) to 50 μl RPMI-1640 (C-), (ii) to 50 μg/ml or 100 μg/ml 
polymyxin B alone (Pol50 and Pol100 respectively), (iii) to 50 
μg/ml or 100 μg/ml polymyxin B supplemented with 5 μg 
rApxIIIA during the second hour (Pol50/Apx and Pol100/
Apx), or after a one-hour exposition either (iii) to 5 μg rApx-
IIIA alone (Apx) or (iv) to paraformaldehyde 10% (C+). Val-
ues are means ± SDs from three representative experiments. 
Asterisks (1): PI-positive cell densities significantly higher 
than that recorded in C-, Pol50 and Pol100 sets of experi-
ments (P < 0.0001). PI-positive cell densities retrieved from 
Pol50/Apx, Pol100/Apx and rApxIIIA groups were not statis-
tically different from each other (P > 0.5). B. Effect of anti-
ApxIIIA antibodies incorporation on rApxIIIA-containing 
crude toxin preparation cytotoxicity towards porcine 
PBMCs. The fraction of PI-positive cells was measured by 
flow cytometry after a one-hour exposition (i) to 50 μl 
RPMI-1640 (C-), (ii) to a monospecific anti-ApxIIIA polyclo-
nal antiserum diluted 1/1,000 (Ab-Apx), (iii) to a mix of rApx-
IIIA (0.31 or 0.16 μg) and the anti-ApxIIIA polyclonal 
antiserum diluted 1/1,000 (Ab-Apx + Apx), and (iv) to rApxI-
IIA alone (Apx) (0.31 or 0.16 μg). Values are means ± SDs 
from three representative experiments. Asteriks (2): positive 
cell densities significantly higher than that recorded in Ab-
Apx + Apx sets of experiments (P < 0.01).BMC Research Notes 2008, 1:121 http://www.biomedcentral.com/1756-0500/1/121
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the development of cell death. The cytotoxicity is dose-
dependent, develops within minutes, is not susceptible to
polymyxin B and is dramatically abated by toxin preincu-
bation with a monospecific polyclonal antiserum directed
against ApxIIIA, which suggests that the cytopathogenic
activity detected is exercised by ApxIIIA. The cytotoxicity
recorded is specifically directed towards porcine and wild
boar PBMCs, even if ruminant leukocytes show slight sus-
ceptibility too. Overall, we have shown that ApxIIIA
shares many functional characteristics with other RTX tox-
ins, i.e. LtxA from A. actinomycetemcomitans [24], LktA
from M. haemolytica [25], HlyA from E. coli [26] or CyaA
from B. pertussis [27], which suggests that it might use the
same receptors, the leukocyte β2-integrins [11-18].
Recombinant expression of porcine CD11a [28] and
CD18 [29] in ApxIIIA-resistant cells could answer this
question in the future.
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